New Two-Drug attack aims to outsmart resistant lung cancer
NCT ID NCT05845671
Summary
This early-stage study is testing whether adding a new drug called amivantamab to standard targeted therapies can help control advanced lung cancer that has started growing again. It will involve about 12 adults whose cancer has specific genetic changes and has become resistant to their current medication. The main goals are to find a safe dose and see if the two-drug combination can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Outpatient CTRC
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.